# Monograph Capital

Monograph Capital is a Private Equity based in London, United Kingdom.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** London, United Kingdom
- **Region:** Europe
- **Address:** London, United Kingdom
- **Founded:** 2021
- **Assets under management:** Undisclosed
- **Website:** monograph.bio
- **LinkedIn:** https://www.linkedin.com/company/monograph-capital

## Regulatory record

- **Reports private funds:** No

## About

Monograph Capital finds and funds innovative life sciences companies, aiming to help translate promising science into potential, life-changing treatments for patients around the world. They are a transatlantic team focused on sourcing leading scientific innovation and supporting the development of strong companies across boundaries. They combine differentiated sourcing, long-standing relationships with pharma, deep medical expertise, and seasoned operating experience to help create value for company partners and investors.

## Sectors

- Biotechnology
- Life Sciences
- Pharmaceuticals
- Digital Health
- AI/ML

## Offices

- San Francisco, CA
- Fort Worth, TX

## People

- Fred Cohen — Partner and Chairman
- Tim Funnell — Partner
- Charles Conn — Partner
- Matt McAviney — Partner
- Mike LaGatta — Partner and COO
- Jennifer Shah — Head of Capital Formation

## Questions

### Who runs investment decisions at Monograph Capital?

Fred Cohen serves as Partner and Chairman and sits on the firm's Investment Committee. He co-founded the firm in 2021 after leading TPG's biotechnology venture efforts since 2001. The investment team includes partners Tim Funnell, Charles Conn, and Matt McAviney, all of whom carry advanced scientific or medical degrees and share decision-making authority through the Investment Committee.

### How does Monograph Capital source proprietary deal flow?

Monograph combines long-standing relationships with pharmaceutical companies, deep academic networks—its principals include former UCSF professors and Oxford-trained pharmacologists—and a company-formation model where the firm itself creates new companies around promising science. Partners Fred Cohen and Tim Funnell spent their prior careers at TPG, Vida Ventures, Syncona, and Third Rock Ventures, each of which built deal-sourcing engines grounded in academic medical centers.

### Does Monograph Capital participate in fund commitments or only direct deals?

Monograph invests directly in portfolio companies as a lead or co-lead investor in venture-stage financings. There is no publicly available evidence that the firm makes fund commitments to outside managers. Its website, portfolio, and team biographies all describe a direct-investment, company-building strategy.

### How is Monograph Capital related to Ouro Medicines' acquisition by Gilead?

Monograph co-founded Ouro Medicines in partnership with GSK and co-led its Series A in December 2024 alongside TPG Life Sciences Innovations, NEA, and Norwest Venture Partners. In Q2 2026, Gilead Sciences signed a definitive agreement to acquire Ouro for up to $2.175 billion. Monograph's Jaideep Dudani served as founding CEO of Ouro.

### What is Monograph Capital's known posture on co-investments alongside external GPs?

Monograph actively co-invests with other specialist life sciences investors. It co-led deals with NEA (AviadoBio, 2021), co-led with Arkin Bio Capital (Nocion, 2024), participated alongside Enavate Sciences and TPG (Sudo, 2023), and co-led with 5AM Ventures and OrbiMed (Prolynx). The firm does not describe a formal co-investment program for LPs beyond its own fund structure.

## Related profiles

- [Monogram Capital Partners](https://altss.com/profile/monogram-capital-partners)
- [Monolith Management](https://altss.com/profile/monolith-management)

---

Last updated: 2026-08-11T15:07:26.757Z

Canonical page: https://altss.com/profile/monograph-capital-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology